What is the ROCE (Return on Capital Employed) of Celldex Therapeutics this year?
The ROCE of Celldex Therapeutics is -0.33 undefined this year.
Celldex Therapeutics ROCE 2024
Celldex Therapeutics ROCE
-0.33
Ticker
CLDX
ISIN
US15117B2025
WKN
A2PEAB
In 2024, Celldex Therapeutics's return on capital employed (ROCE) was -0.33, a 7.71% increase from the -0.31 ROCE in the previous year.
Celldex Therapeutics Aktienanalyse
What does Celldex Therapeutics do?
Celldex Therapeutics is an American company specializing in the development and research of therapeutics for diseases of the immune system and cancer. The company was founded in 2004 and is headquartered in Hampton, New Jersey. Celldex Therapeutics was originally established as a subsidiary of Alteon Inc., which focused on developing drugs for heart diseases. In 2004, the company became independent. Celldex Therapeutics has continuously invested in the development of new medicines for various areas of oncology. Its business model is based on the development and marketing of innovative therapeutics. The company collaborates closely with leading research institutions in the field of immunology and oncology to develop new therapies. Celldex Therapeutics also has partnerships with major pharmaceutical companies such as Pfizer, Roche, and Bristol-Myers Squibb. The company is divided into different divisions, including the development of vaccines and immunotherapies for various types of cancer, as well as the development of protein therapeutics for the treatment of inflammatory diseases and other immune system disorders. Celldex Therapeutics has already launched several products or is currently developing them, including CDX-1127, a immunomodulatory antibody for cancer treatment; CDX-1135, a novel vaccine against the Epstein-Barr virus; CDX-1401, an immunotherapy for various types of cancer based on dendritic cells; and Glembatumumab vedotin, an antibody-drug conjugate for the treatment of different types of cancer. In summary, Celldex Therapeutics is a biotech company specialized in innovative therapies for cancer and immune system diseases. The company collaborates with research institutions and pharmaceutical companies to bring its products to patients. Its wide portfolio and expertise contribute to improving patient care. Celldex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Celldex Therapeutics's Return on Capital Employed (ROCE)
Celldex Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Celldex Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Celldex Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Celldex Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Celldex Therapeutics stock
How has the ROCE (Return on Capital Employed) of Celldex Therapeutics developed compared to the previous year?
The ROCE of Celldex Therapeutics has increased by 7.71% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Celldex Therapeutics?
A high Return on Capital Employed (ROCE) indicates that Celldex Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Celldex Therapeutics?
A low ROCE (Return on Capital Employed) can indicate that Celldex Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Celldex Therapeutics impact the company?
An increase in the ROCE of Celldex Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Celldex Therapeutics affect the company?
A decrease in ROCE of Celldex Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Celldex Therapeutics?
Some factors that can affect Celldex Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Celldex Therapeutics so important for investors?
The ROCE of Celldex Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Celldex Therapeutics take to improve the ROCE?
To improve the ROCE, Celldex Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Celldex Therapeutics pay?
Over the past 12 months, Celldex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celldex Therapeutics is expected to pay a dividend of 0 USD.
What is the dividend yield of Celldex Therapeutics?
The current dividend yield of Celldex Therapeutics is .
When does Celldex Therapeutics pay dividends?
Celldex Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Celldex Therapeutics?
Celldex Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Celldex Therapeutics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Celldex Therapeutics located?
Celldex Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Celldex Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Celldex Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did Celldex Therapeutics pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of Celldex Therapeutics in the year 2023?
In the year 2023, Celldex Therapeutics distributed 0 USD as dividends.
In which currency does Celldex Therapeutics pay out the dividend?
The dividends of Celldex Therapeutics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Celldex Therapeutics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Celldex Therapeutics
Our stock analysis for Celldex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celldex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Celldex Therapeutics Revenue
- Celldex Therapeutics Net Income
- Celldex Therapeutics P/E
- Celldex Therapeutics P/S
- Celldex Therapeutics EBIT
- Celldex Therapeutics Dividend
- Celldex Therapeutics Stocks
- Celldex Therapeutics Market capitalization
- Celldex Therapeutics Debt
- Celldex Therapeutics Liabilities
- Celldex Therapeutics Equity
- Celldex Therapeutics AAQS
- Celldex Therapeutics Employees
- Celldex Therapeutics ROE
- Celldex Therapeutics ROA
- Celldex Therapeutics ROCE
